| 刘小兵,李晨彦,曾 群,贺喜强,郭凌志.如意珍宝丸联合依达拉奉治疗蛛网膜下腔出血后脑血管痉挛的临床研究[J].,2023,(14):2736-2740 |
| 如意珍宝丸联合依达拉奉治疗蛛网膜下腔出血后脑血管痉挛的临床研究 |
| Clinical Study of Ruyi Zhenbao Pill Combined with Edaravone in the Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage |
| 投稿时间：2023-02-05 修订日期：2023-02-28 |
| DOI：10.13241/j.cnki.pmb.2023.14.026 |
| 中文关键词: 如意珍宝丸 依达拉奉 蛛网膜下腔出血 脑血管痉挛 临床疗效 |
| 英文关键词: Ruyi Zhenbao pill Edaravone Subarachnoid hemorrhage Cerebral vasospasm Clinical efficacy |
| 基金项目:国家自然科学基金项目（81801136） |
|
| 摘要点击次数: 366 |
| 全文下载次数: 308 |
| 中文摘要: |
| 摘要 目的：探讨如意珍宝丸联合依达拉奉治疗蛛网膜下腔出血（SAH）后脑血管痉挛（CVS）的临床疗效。方法：选取我院2021年3月~2022年4月期间收治的138例SAH后CVS患者。按照随机数字表法分为对照组（69例，依达拉奉治疗）和研究组（69例，如意珍宝丸联合依达拉奉治疗）。对比两组临床疗效、格拉斯哥昏迷指数（GCS）评分、Barthel指数、神经功能缺损评分（NIHSS）评分、大脑血流动力学相关指标、血管内皮功能指标及不良反应发生率。结果：研究组的临床总有效率高于对照组（P<0.05）。治疗2周后，研究组的GCS评分、Barthel指数高于对照组，NIHSS低于对照组（P<0.05）。治疗2周后，研究组的血管内皮生长因子（VEGF）、内皮素-1（ET-1）低于对照组，一氧化氮（NO）、降钙素基因相关肽（CGRP）高于对照组（P<0.05）。治疗2周后，研究组的大脑中动脉平均流速（MCA-Vm）、颈内动脉颅外段平均流速（VICA-Vm）、Li指数较对照组低（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：如意珍宝丸联合依达拉奉治疗SAH后CVS患者，可减轻神经功能损伤，改善血管内皮功能和脑血流速度，提高生活自理能力。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy of Ruyi Zhenbao pill combined with edaravone in the treatment of cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH). Methods: 138 patients with CVS after SAH who were admitted to our hospital from March 2021 to April 2022 were selected. According to random number table method, they were divided into control group (69 cases, edaravone treatment) and study group (69 cases, Ruyi Zhenbao pill combined with edaravone treatment). The clinical efficacy, Glasgow coma scale (GCS) score, Barthel index, National Institutes of Health Stroke Scale (NIHSS) score, cerebral hemodynamic related indexes,vascular endothelial function indexes and the incidence of adverse reactions were compared in the two groups. Results: The total clinical effective rate in the study group was higher than that in the control group(P<0.05). 2 weeks after treatment, the GCS score and Barthel index in the study group were higher than those in the control group, and the NIHSS was lower than that in the control group (P<0.05). 2 weeks after treatment, the vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1) in the study group were lower than those in the control group, while nitric oxide (NO) and calcitonin gene-related peptide (CGRP) were higher than those in the control group (P<0.05). 2 weeks after treatment, the mean flow velocity of middle cerebral artery (MCA-Vm), the mean flow velocity of external carotid artery (VICA-Vm) and Li index in the study group were lower than those in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Ruyi Zhenbao pill combined with edaravone in the treatment of patients with CVS after SAH can reduce neurological injury, improve vascular endothelial function and cerebral blood flow velocity, and improve self-care ability. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
